"Receptors, Interleukin-6" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cell surface receptors that are specific for INTERLEUKIN-6. They are present on T-LYMPHOCYTES, mitogen-activated B-LYMPHOCYTES, and peripheral MONOCYTES. The receptors are heterodimers of the INTERLEUKIN-6 RECEPTOR ALPHA SUBUNIT and the CYTOKINE RECEPTOR GP130.
| Descriptor ID |
D019947
|
| MeSH Number(s) |
D12.776.543.750.705.852.420.400
|
| Concept/Terms |
Receptors, Interleukin-6- Receptors, Interleukin-6
- Receptors, Interleukin 6
- IL-6 Receptors
- IL 6 Receptors
- Receptors, IL-6
- Receptors, IL 6
- IL6 Receptors
- Receptors, IL6
- Interleukin 6 Receptor
- Receptor, Interleukin 6
- Interleukin-6 Receptors
- Interleukin 6 Receptors
- IL-6 Receptor
- IL 6 Receptor
- Receptor, IL-6
- IL6 Receptor
- Receptor, IL6
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Interleukin-6".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Interleukin-6".
This graph shows the total number of publications written about "Receptors, Interleukin-6" by people in this website by year, and whether "Receptors, Interleukin-6" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 1 | 2 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Interleukin-6" by people in Profiles.
-
The IL-6R and Bmi-1 axis controls self-renewal and chemoresistance of head and neck cancer stem cells. Cell Death Dis. 2021 10 23; 12(11):988.
-
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia. Clin Pharmacol Ther. 2021 03; 109(3):688-696.
-
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. J Immunother Cancer. 2020 04; 8(1).
-
Interleukin-6 Reduces ß-Cell Oxidative Stress by Linking Autophagy With the Antioxidant Response. Diabetes. 2018 08; 67(8):1576-1588.
-
A mathematical model for IL-6-mediated, stem cell driven tumor growth and targeted treatment. PLoS Comput Biol. 2018 01; 14(1):e1005920.
-
Vitamin D and corticotropin-releasing hormone in term and preterm birth: potential contributions to preterm labor and birth outcome. J Matern Fetal Neonatal Med. 2018 Nov; 31(21):2911-2917.
-
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013 Jun 27; 121(26):5154-7.
-
Essential role of neutrophil mobilization in concanavalin A-induced hepatitis is based on classic IL-6 signaling but not on IL-6 trans-signaling. Biochim Biophys Acta. 2011 Mar; 1812(3):290-301.
-
Role of IL-6 trans-signaling in CCl4induced liver damage. Biochim Biophys Acta. 2010 Nov; 1802(11):1054-61.
-
Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration. J Autoimmun. 2010 Feb; 34(1):29-37.